Core Insights - The article discusses the transformation of Chinese companies, particularly those from Jinan, from being mere exporters to becoming integral players in global supply chains, emphasizing the shift from selling products to providing comprehensive solutions [1][4]. Group 1: Export Growth and Strategy - Jinan's total import and export value reached 258.81 billion yuan from January to November 2025, marking a 24.9% year-on-year increase, the highest in the province [1]. - Qilu Pharmaceutical has transitioned from exporting raw materials to finished pharmaceutical products, with 34 products now exported to the U.S., establishing a significant presence in major regulatory markets [2]. - In the first three quarters of the year, Qilu Pharmaceutical achieved an export value of 869 million USD, reflecting an 11% increase [2]. Group 2: Innovative Business Models - Qilu Pharmaceutical's ability to provide a reliable management system has allowed it to be recognized as a trusted solution provider, enhancing its international standing [2]. - Jinan Kehong Biopharmaceutical has adopted a "global selection + global coverage" model, establishing a network across nearly 70 countries and regions, and integrating over 40 domestic pharmaceutical products into its offerings [3]. Group 3: Localized Operations and Ecosystem Building - China National Heavy Duty Truck Group has shifted its business model from trade to a comprehensive global operation covering R&D, manufacturing, and service, reflecting a significant change in operational logic [4][5]. - The company has localized its workforce in Australia, achieving over 50% local team composition, which has helped it quickly rise to a top-five market position [5]. Group 4: Advanced Technology and Market Positioning - Shandong Tianyue Advanced Technology has emerged as a leader in the silicon carbide substrate market, achieving a 47.53% share of overseas revenue and establishing partnerships with top semiconductor manufacturers [7]. - Huaxi Biotechnology has invested significantly in a synthetic biology pilot transformation platform, aiming to address global challenges in biomanufacturing and expand its market presence [8][9]. Group 5: Comprehensive Solutions and Industry Integration - Shandong High-Speed Group is transitioning from an engineering contractor to a comprehensive solution provider, exemplified by its involvement in high-profile projects in Serbia and Bangladesh [6]. - The company has developed a collaborative ecosystem with five regional companies and ten specialized firms to support local enterprises in international markets [6].

Core Insights - The article highlights the transformation of China's pharmaceutical industry from a "big pharmaceutical country" to a "strong pharmaceutical country," emphasizing the importance of high-quality development and innovation in the sector [2][3] Group 1: Event Overview - The "High-Quality Development Research Tour of Domestic Medicines" was successfully held in Jinan, Shandong, from June 4 to June 6, 2025, organized by the China Pharmaceutical News Information Association and Beijing Daily Client [1] - The event involved over 20 major media outlets, focusing on the research and innovation platform, quality management system, and intelligent production base of Qilu Pharmaceutical [1] Group 2: Qilu Pharmaceutical's Achievements - Qilu Pharmaceutical has won 7 National Science and Technology Progress Awards and has 208 products listed in the National Medical Insurance Directory as of June 2025 [2] - The company has achieved leadership in the industry in terms of consistency evaluation, first-time evaluations, and national procurement bidding [2] - Qilu's R&D investment has increased from 5%-8% of sales revenue to 10%-12%, with an expected cumulative investment exceeding 20 billion yuan during the 14th Five-Year Plan period [3] Group 3: International Expansion - Qilu Pharmaceutical is the only domestic company exporting formulations to major regulatory markets including Europe, the US, Japan, Australia, and Canada, with 38 products holding the top market share in their respective regions [4] - The company's export revenue reached 1.02 billion USD in 2024 [4] Group 4: Technological Innovations - Qilu has developed groundbreaking technologies such as dual-function combination antibody preparation technology and large-scale cell culture technology, establishing an internationally leading MabPair combination antibody technology platform [6] - The company has implemented fully automated production lines, ensuring quality consistency and traceability throughout the production process [5] Group 5: Industry Dialogue - A seminar titled "Quality Leads, Good Medicines Accessible" was held during the research tour, where experts discussed the need for improved public perception of domestic medicines and the importance of collaborative efforts among media, academia, and regulatory bodies [6] - Qilu has 15 products among those selected in national procurement that rank highly in the US market [6] Group 6: Future Directions - The "High-Quality Development Research Tour of Domestic Medicines" will continue to focus on the pharmaceutical industry, expanding research to more domestic pharmaceutical companies across the country [7]

Core Points - The event "Service Multinational Companies: Shandong in Action" highlights Shandong's commitment to attracting foreign investment, showcasing 236 Fortune 500 companies involved in 943 projects in the province [1][2] - Shandong aims to enhance its global cooperation with multinational companies as part of its strategy for high-quality development and open economic growth [2][3] Group 1: Policy Support - Shandong has implemented various policies to create a favorable investment environment, including the "Implementation Opinions on Building a New High Ground for Opening Up" and measures to optimize foreign investment [3][5] - The province has introduced a comprehensive action plan for stabilizing foreign investment by 2025, focusing on expanding autonomous openness and enhancing investment promotion [3][5] - Specific measures in the pharmaceutical sector include financial incentives for innovative drugs, with up to 30 million yuan in funding support for first-class innovative drugs [3][6] Group 2: Investment Environment - Shandong has been recognized as one of the top 10 provinces for business environment for four consecutive years, emphasizing a market-oriented, legal, and international business climate [5][6] - The province has established a "Service Ambassador" system for foreign investment, with over 3,000 ambassadors providing real-time support to foreign enterprises [5][6] - The successful collaboration with AstraZeneca exemplifies Shandong's integrated approach to facilitating foreign investment through continuous communication and problem-solving [5][6] Group 3: Economic Contribution - Multinational companies significantly contribute to Shandong's economy, with 2,769 foreign-funded industrial enterprises accounting for 14.2% of the province's industrial revenue and 22.6% of its profits [9][10] - Major global firms like Henkel, AstraZeneca, and HP have established a strong presence in Shandong, fostering influential industrial clusters in materials, automotive manufacturing, and information technology [9][10] - Shandong's collaboration with multinational companies focuses on technological innovation and supply chain cooperation, leading to the establishment of key projects and enhancing the province's industrial capabilities [9][10]